Compare Crispr Therapeutics AG (CRSP) vs Electronic Arts Inc. (EA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Electronic Arts Inc. — how do they compare? Crispr Therapeutics AG trades at $51.6 (market cap $4.97B), while Electronic Arts Inc. trades at $207.67 (market cap $51.82B). The key difference: Electronic Arts Inc. is far larger — about 10.4× Crispr Therapeutics AG's market cap, and Electronic Arts Inc. pays a 0.37% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EA | |
|---|---|---|
Market Cap | $4.97B | $51.82B |
Sector | Health | Technology |
52-Week High | $76.78 | $206.65 |
52-Week Low | $44.34 | $147.79 |
Enterprise Value | $3.32B | $50.39B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Electronic Arts (EA) trades at $206.35, down 0.03% on the day, with a bullish technical signal from moving averages and mixed earnings performance including a recent Q4 2025 beat. The company maintains strong profitability with a 78.97% gross margin and 11.78% net margin, though valuation ratios like P/E of 58.79 appear elevated. Recent launches of EA SPORTS College Football 27 and UFC 6, plus the new EA Advertising platform, highlight ongoing growth initiatives.
Outlook is cautiously optimistic given analyst consensus leaning Hold (56.06%) versus Buy (43.94%), with risks including earnings volatility and high valuation. The potential $55 billion acquisition by Saudi investors, pending EU approval, could significantly impact shareholder value, while consistent cash flow from operations supports dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →
